A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD

Key Inclusion Criteria: * Men and women with newly diagnosed active Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD), diagnosed by a retinal specialist with all the following characteristics and ophthalmic inclusion criteria applied to the study eye, as assessed by a central reader: * Has been examined by a retinal specialist and found to be eligible to receive Intravitreal Aflibercept Injection (IAI) in the study eye. * No prior treatment for Neovascular Age-Related Macular Degeneration (nAMD) in the study eye. * Study eye has not undergone pars plana vitrectomy or glaucoma filtering surgery. * Participation in studies of investigational drugs must have been discontinued within 30 days or 5 half-lives of the drug (whichever was longer) prior to screening. * Central subfield thickness (CST) thickness ≥ 250 microns on SD-OCT (spectral domain OCT) (exclusive of subretinal pigment epithelial fluid, inclusive of SRF). * Presence of SRF (subretinal fluid) and/or IRF (intraretinal fluid) on SD-OCT. * Total lesion size not greater than 12 disc areas (30.48 mm2) (1 disc area = 2.54 mm2) on FA (fluorescein angiography). * If present, subretinal hemorrhage must comprise \< 50% of the total lesion area on FA, SD-OCT, or FP/FAF (fundus photography/fundus autofluorescence). * No subfoveal fibrosis or atrophy on FA, SD-OCT, or FP/FAF. * Active CNV (choroidal neovascularization) membranes with subfoveal leakage or juxtafoveal leakage too close for laser photocoagulation. * BCVA (Best Corrected Visual Acuity) in the study eye between 70 and 24 letters inclusive. * Body mass index (BMI) between (and inclusive of) 18 and 40 at screening. Key Exclusion Criteria: * Participation in studies of investigational drugs within 30 days or 5 half-lives of the drug (whichever was longer) prior to screening. * Known hypersensitivity to the active substance or any of the excipients of AKST4290 or aflibercept. * Active or suspected ocular or periocular infection and/or active, severe intraocular inflammation. * Any form of macular degeneration that is not age-related (e.g., Best's disease, Stargardt's disease, Sorsby's disease). * Additional disease in the study eye that could compromise BCVA (i.e., uncontrolled glaucoma (IOP \>24) with visual field loss, clinically significant diabetic macular edema, history of ischemic optic neuropathy or retinal vascular occlusion, vitreomacular traction, high myopia \> 6 diopters, or genetic disorders such as retinitis pigmentosa). * Presence of RPE (Retinal Pigment Epithelium) tears or rips in the study eye. * Anterior segment and vitreous abnormalities in the study eye that would preclude adequate visualization with FP/FAF, FA, or SD-OCT. * Intraocular surgery in the study eye within 3 months prior to screening. * Aphakia or total absence of the posterior capsule (yttrium aluminum garnet \[YAG\] laser capsulotomy permitted in an eye with a posterior chamber intraocular lens if performed a minimum of 1 month prior to enrollment) in the study eye. * Known allergy to fluorescein sodium. * Significant alcohol or drug abuse within past 2 years. * Based on ECG (electrocardiogram) reading, subjects with a risk of QT prolongation. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.